EUR 0.0
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -7.04 Million EUR | -203.71% |
2022 | -2.31 Million EUR | 80.73% |
2021 | -12.02 Million EUR | 19.92% |
2020 | -15.01 Million EUR | -34.39% |
2019 | -11.17 Million EUR | 2.55% |
2018 | -11.46 Million EUR | 6.73% |
2017 | -12.29 Million EUR | 3.95% |
2016 | -12.79 Million EUR | -4.7% |
2015 | -12.22 Million EUR | -117.28% |
2014 | -5.62 Million EUR | -39.15% |
2013 | -4.04 Million EUR | -10.4% |
2012 | -3.66 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -233.5 Thousand EUR | 0.0% |
2024 Q1 | -233.5 Thousand EUR | 85.13% |
2023 Q4 | -1.57 Million EUR | -0.06% |
2023 Q2 | -4.26 Million EUR | -118.71% |
2023 FY | -7.58 Million EUR | -227.09% |
2023 Q1 | -1.95 Million EUR | -112.01% |
2023 Q3 | -1.56 Million EUR | 63.22% |
2022 Q2 | -4.35 Million EUR | 0.0% |
2022 Q4 | -920 Thousand EUR | 0.0% |
2022 FY | -2.31 Million EUR | 80.73% |
2022 Q3 | -920 Thousand EUR | 78.88% |
2021 Q2 | -6.49 Million EUR | 0.0% |
2021 FY | -12.02 Million EUR | 19.92% |
2021 Q4 | -7.27 Million EUR | 0.0% |
2020 Q2 | -10.13 Million EUR | 0.0% |
2020 Q4 | -7.54 Million EUR | 0.0% |
2020 FY | -15.01 Million EUR | -34.39% |
2019 FY | -11.17 Million EUR | 2.55% |
2019 Q2 | -7.11 Million EUR | 0.0% |
2019 Q4 | -7.38 Million EUR | 0.0% |
2018 Q4 | -7.58 Million EUR | 0.0% |
2018 FY | -11.46 Million EUR | 6.73% |
2017 FY | -12.29 Million EUR | 3.95% |
2016 FY | -12.79 Million EUR | -4.7% |
2015 FY | -12.22 Million EUR | -117.28% |
2014 Q3 | -1.08 Million EUR | 0.0% |
2014 Q4 | -1.88 Million EUR | -74.35% |
2014 FY | -5.62 Million EUR | -39.15% |
2013 Q4 | -1.31 Million EUR | 0.0% |
2013 FY | -4.04 Million EUR | -10.4% |
2012 FY | -3.66 Million EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Boiron SA | 42.29 Million EUR | 116.647% |
Laboratorios Farmaceuticos Rovi, S.A. | 220.25 Million EUR | 103.196% |
Vetoquinol SA | 74.26 Million EUR | 109.48% |
Valneva SE | -82.08 Million EUR | 91.424% |
AB Science S.A. | -13.42 Million EUR | 47.576% |
Nanobiotix S.A. | -26.77 Million EUR | 73.711% |
PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 70.245% |
Vivoryon Therapeutics N.V. | -28.83 Million EUR | 75.587% |
ABIVAX Société Anonyme | -127.37 Million EUR | 94.473% |
Formycon AG | -369 Thousand EUR | -1807.859% |